Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 17Glioblastoma 8Esophageal Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Rectal Neoplasms 7Oropharyngeal Neoplasms 7Breast Neoplasms 7Mouth Neoplasms 6Glioma 6Triple Negative Breast Neoplasms 4Lung Neoplasms 4Laryngeal Neoplasms 4Head and Neck Neoplasms 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Stomach Neoplasms 3Sarcoma 3Pancreatic Neoplasms 3Multiple Myeloma 3Neuroblastoma 2Neoplasms 2Nasopharyngeal Carcinoma 2Melanoma 2Medulloblastoma 2Hypopharyngeal Neoplasms 2Ganglioneuroblastoma 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Sinonasal Squamous Cell Carcinoma × Radiation × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡